Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker
Karel G.M. Moons(University Medical Center Utrecht), Diederick E. Grobbee(University Medical Center Utrecht), André Pascal Kengne(South African Medical Research Council), Douglas G. Altman(Unknown), Patrick Royston(Royal Statistical Society), Mark Woodward(UNSW Sydney), Yvonne Vergouwe(Erasmus MC)
Cited by 882
Related Papers
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
|Annals of Internal Medicine|2015|8.2k
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
|The Lancet|2010|4.2k
Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations
|European Journal of Epidemiology|2016|3.1k
Evaluating non-randomised intervention studies
|Health Technology Assessment|2003|2.9k